Credit Suisse Ag Moon Lake Immunotherapeutics Call Options Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MLTX
# of Institutions
135Shares Held
56MCall Options Held
379KPut Options Held
402K-
Bvf Inc San Francisco, CA21.8MShares$914 Million32.73% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$357 Million24.56% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.58MShares$108 Million1.56% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.31MShares$97.1 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.28MShares$96 Million0.23% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.55B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...